The aging hemophilia patient [0.03%]
老龄化血友病患者
Magdalena Lewandowska,Ming Y Lim
Magdalena Lewandowska
Advances in the development of safe and effective treatments for hemophilia over the past century have significantly increased the life expectancy of persons with hemophilia (PwH). As a result, clinicians are now encountering age-related co...
New therapies in hemophilia: extend the half-life, mimic, or rebalance? [0.03%]
血友病的新疗法：延长半衰期、模拟或再平衡？
Mark T Reding
Mark T Reding
The treatment landscape for hemophilia has evolved rapidly over the past decade, with the approval of several therapies with novel mechanisms of action. Extended half-life factor concentrates and nonfactor therapies, including factor VIII m...
Monoclonal gammopathy of renal significance from a hematologic perspective [0.03%]
血液学角度下的肾损害意义的单克隆免疫球蛋白增多症
Eugene Brailovski,Insara S Jaffer,Heather J Landau
Eugene Brailovski
Monoclonal gammopathy of renal significance (MGRS) represents a clinical entity where clonal plasma or B-cell proliferative disorders secrete a monoclonal protein that leads to renal damage without meeting the diagnostic criteria for overt ...
Amy Moskop,Julie-An Talano
Amy Moskop
Allogeneic hematopoietic cell transplantation is a potentially curative therapy for patients with both malignant and nonmalignant disorders. To select the optimal donor for allogeneic hematopoietic cell transplantation, the first step is to...
Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML? [0.03%]
适合所有人的三联方案：在不适合强化疗的急性髓系白血病患者中采用基因组学无关的治疗策略改善地西他滨或阿扎胞苷联合维奈克拉疗法？
William Nicol,Andrew H Wei
William Nicol
Combined hypomethylating agent (HMA) plus venetoclax (Ven) therapy enables most older patients with acute myeloid leukemia (AML) to achieve clinical remission. Key objectives are now aimed at developing new triplet combinations to circumven...
Tailored treatment of acute immune-mediated thrombotic thrombocytopenic purpura [0.03%]
个体化治疗急性免疫介导的血栓性血小板减少性紫癜
Linus Alexander Völker,Paul Thomas Brinkkötter
Linus Alexander Völker
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare but life-threatening disease caused by an autoantibody-mediated mechanism of deficiency of the von Willebrand factor (VWF)-cleaving protease ADAMTS13. Novel therapeutic pr...
The varieties of therapeutic experience: navigating treatment options for patients with PNH [0.03%]
治疗性经验的各种形式——PNH患者的治疗选择导航
Marc Bienz,Christopher J Patriquin
Marc Bienz
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired disorder of complement dysregulation, predisposing patients to complications of intravascular hemolysis, thrombophilia, and marrow failure, with a high risk of mortality without ...
The role of MRD monitoring and options for CLL management in relapsed/refractory disease [0.03%]
MRD监测的作用以及在复发/难治性CLL中的治疗选择
Brian Sworder,Tanya Siddiqi
Brian Sworder
The role of minimal residual disease (MRD) testing is well defined in curable hematological malignancies like acute lymphoblastic leukemia. However, in chronic lymphocytic leukemia (CLL), which is an incurable low-grade lymphoma, MRD is mos...
Molecular subtypes of DLBCL: are we ready to translate our knowledge into the change of treatment paradigms? [0.03%]
弥漫性大B细胞淋巴瘤的分子亚型：我们准备好将研究发现转化为新的治疗模式吗？
Sarah C Rutherford
Sarah C Rutherford
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with disparate outcomes. While about two-thirds of patients have historically been cured with standard frontline chemoimmunotherapy, those who relapse or are refractory have t...
The right patient, the right treatment: tailoring sickle cell disease care [0.03%]
合适的患者，合适的治疗：精准化镰状细胞病的诊治
Sheinei Alan,Payal Desai
Sheinei Alan
Sickle cell disease (SCD) remains the most common monogenic disorder worldwide, yet more than a century after its formal discovery, our treatment options and approach to care remain underdeveloped. Despite scientific progress, care for SCD ...